Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ELISA microarray technology as a high-throughput system for cancer biomarker validation.

Richard C Zangar1, Don S Daly, Amanda M White

  • 1Pacific Northwest National Laboratory, PO Box 999, Richland, WA 99352, USA. richard.zangar@pnl.gov

Expert Review of Proteomics
|February 1, 2006
PubMed
Summary

Discovering cancer biomarkers is challenging due to variability and rarity. Enzyme-linked immunosorbent assay (ELISA) microarray technology offers a promising solution for validating protein biomarkers for cancer screening.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>C. elegans</i> food choice exhibits effort discounting-like behavior.

eLife·2025
Same author

Behavioral and genetic analysis of the effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) in C. elegans.

PloS one·2025
Same author

Behavioral and genetic analysis of the effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) in <i>C. elegans</i>.

bioRxiv : the preprint server for biology·2025
Same author

<i>C. elegans</i> food choice exhibits effort discounting-like behavior.

bioRxiv : the preprint server for biology·2025
Same author

FREDA: A Web Application for the Processing, Analysis, and Visualization of Fourier-Transform Mass Spectrometry Data.

Rapid communications in mass spectrometry : RCM·2024
Same author

PMart Web Application: Marketplace for Interactive Analysis of Panomics Data.

Journal of proteome research·2023

Area of Science:

  • Biomarker Discovery
  • Cancer Screening
  • Proteomics

Background:

  • Significant gap exists between discovering potential cancer biomarkers and validating their clinical utility.
  • Biomarker validation faces challenges from population diversity and tumor heterogeneity, impacting assay reliability.
  • High assay specificity is crucial for cancer screening due to the rarity of most cancers to minimize false positives.

Purpose of the Study:

  • To review current Enzyme-linked immunosorbent assay (ELISA) microarray technology for protein biomarker validation.
  • To discuss advancements needed to enhance reproducibility and throughput for cancer biomarker evaluation.
  • To address the challenges in assessing the real value of protein biomarkers for cancer screening.

Main Methods:

  • Review of Enzyme-linked immunosorbent assay (ELISA) microarray technology.

Related Experiment Videos

  • Discussion of technological advancements for biomarker validation.
  • Analysis of requirements for high-throughput and reproducible biomarker assessment.

    • Main Results:

    • ELISA microarray technology enables simultaneous quantification of multiple proteins.
    • This technology has the potential to accelerate the validation of protein biomarkers.
    • Addressing variability and specificity are key to successful biomarker validation.

    Conclusions:

    • ELISA microarray technology shows promise for accelerating protein biomarker validation in cancer screening.
    • Further technological advances are necessary to meet the demands of reproducibility and throughput for clinical applications.
    • Overcoming challenges in biomarker variability and assay specificity is critical for effective cancer screening assays.